Payment overview · 2025
General Payments
$245.22
12 reported records · 9 companies
Healthcare provider profile · identity verified
Michael J. Guese
Allopathic & Osteopathic Physicians|Internal Medicine · DENVER, CO · NPI 1669513628
Verified facts
What the public records show
CMS Open Payments records show Michael J. Guese received $245.22 in general payments during 2025 across 12 reported records.
GlaxoSmithKline, LLC. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.90 | 18.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.03 | 13.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.10 | 12.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $30.17 | 12.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $29.77 | 12.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.64 | 9.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.10 | 9.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.03 | 6.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $13.48 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.22 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 82 |
| Mounjaro | Tirzepatide | 222 | 50 |
| Metformin Hcl | Metformin Hcl | 203 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 48 |
| Losartan Potassium | Losartan Potassium | 173 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 43 |
| Omeprazole | Omeprazole | 135 | 44 |
| Lisinopril | Lisinopril | 129 | 38 |
| Ozempic | Semaglutide | 126 | 22 |
| Gabapentin | Gabapentin | 124 | 34 |
| Eliquis | Apixaban | 122 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 33 |
| Lorazepam | Lorazepam | 105 | 29 |
| Simvastatin | Simvastatin | 92 | 24 |
| Trazodone Hcl | Trazodone Hcl | 92 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 26 |
| Potassium Chloride | Potassium Chloride | 87 | 25 |
| Prednisone | Prednisone | 85 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 21 |
| Furosemide | Furosemide | 62 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 20 |
| Trulicity | Dulaglutide | 56 | 15 |
| Montelukast Sodium | Montelukast Sodium | 52 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 24 |
| Azithromycin | Azithromycin | 51 | 25 |
| Xarelto | Rivaroxaban | 51 | 11 |
| Allopurinol | Allopurinol | 47 | 17 |
| Metformin Hcl Er | Metformin Hcl | 47 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 13 |
| Tramadol Hcl | Tramadol Hcl | 47 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 17 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 11 |
| Jardiance | Empagliflozin | 38 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Pregabalin | Pregabalin | 37 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 18 |
| Finasteride | Finasteride | 36 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | 16 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Famotidine | Famotidine | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.22 · 12 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Kerendia, SAPIEN 3 Ultra RESILIA, SHINGRIX, The Cologuard Plus Collection Kit, UNITHROID, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error